Lauxera Capital Partners has successfully raised €520 million for its second fund, aimed at scaling European healthtech firms in the U.S. market. This significant investment reflects a strong appetite among investors for healthcare technologies that leverage Europe’s engineering and clinical strengths while tapping into the commercial potential of the U.S.
The Paris and San Francisco-based firm exceeded its €500 million target, nearly doubling its inaugural fund size in less than 18 months. This oversubscribed fund was backed by both returning and new investors from Europe, Latin America, and the U.S., indicating a growing interest in healthtech that diverges from traditional biotech investments.
Lauxera's strategy focuses on addressing a critical financing gap for European healthtech companies, which often struggle to transition from regional successes to large-scale international operations, particularly in the U.S. market. Many of these companies have faced challenges in accessing late-stage growth capital, leading to early acquisitions by larger firms or limited growth compared to U.S. counterparts.
The firm plans to invest between €20 million and €50 million in approximately 12 to 15 companies, with an emphasis on sectors such as medical devices and digital health. Lauxera's operational model, which spans both Europe and the U.S., allows portfolio companies to leverage local expertise while maintaining their foundational strengths. As evidenced by their previous successful exit with OrganOx, Lauxera aims to capitalize on the unique advantages European firms hold in engineering and clinical data, positioning them for successful commercialization in the U.S.
This fund not only aims for financial returns but also emphasizes healthcare sustainability metrics, aligning with a broader trend among investment firms to focus on measurable impacts on patient outcomes and healthcare system efficiency.